Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Clinical Sarcoma Research

Fig. 2

From: Cytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendothelioma

Fig. 2

Baseline magnetic resonance imaging (MRI) and positron emission tomography-computed tomography (PET-CT) studies for a 22-year-old man (“Case 2”) with pseudomyogenic hemangioendothelioma. a Baseline contrast-enhanced, fat-saturated T1-weighted axial MR image of the right thigh demonstrates multifocal enhancing lesions in the distal femoral metadiaphysis (short white arrow) and vastus intermedius muscle and subcutaneous fat. b PET-CT fusion image through the distal femurs demonstrates corresponding hypermetabolic activity. Restaging examinations after two cycles of gemcitabine and docetaxel (not shown) did not demonstrate any significant response

Back to article page